drugset / Trial / NCT03671733
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.
Timeline
- Start
- 2018-09-01
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 10 ug | Subcutaneous |
| Subject | Exenatide | Peptide | 2 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 1.8 mg | Subcutaneous |